|
Apr 21
|
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
|
|
Feb 12
|
Beyond Air Third Quarter 2025 Earnings: Beats Expectations
|
|
Feb 10
|
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|
|
Oct 2
|
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
|
|
Sep 28
|
Beyond Air to sell 40.39M shares at 51c in private placement
|
|
Sep 28
|
Beyond Air terminates loan, security agreements with Avenue Capital
|
|
Sep 27
|
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
|
|
Sep 27
|
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
|
|
Sep 27
|
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
|
|
Aug 8
|
Beyond Air First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Aug 6
|
Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
|
|
Jul 23
|
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
|
|
Jun 24
|
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
|
|
Jun 3
|
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
|
|
May 1
|
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
|
|
Mar 20
|
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
|
|
Dec 27
|
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
|
|
Dec 23
|
Beyond Air Independent Director Acquires 102% More Stock
|
|
Dec 21
|
Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc
|
|
Nov 15
|
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
|